We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cathay International Holdings Ld | LSE:CTI | London | Ordinary Share | BMG1965E1030 | COM SHS $0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.75 | 0.50 | 1.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCTI
RNS Number : 7331H
Cathay International Holdings Ld
15 March 2018
Cathay International Holdings Limited
("Cathay" or the "Company")
Notice of Annual Results 2017
Hong Kong, 15 March 2018 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"), today announces the Company will issue its Annual Results for the year ended 31 December 2017 on Monday 9 April 2018.
-Ends-
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Tel: +852 2828 Patrick Sung (Director and Controller) 9289 Consilium Strategic Communications Limited Mary-Jane Elliott / Matthew Neal Tel: +44 (0) / Lindsey Neville 203709 5708
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domes c demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di- calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: http://www.cathay-intl.com.hk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFIVVSISLIT
(END) Dow Jones Newswires
March 15, 2018 03:01 ET (07:01 GMT)
1 Year Cathay International Hol... Chart |
1 Month Cathay International Hol... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions